Turn Therapeutics Inc. is a pharmaceutical and medical device development company built around a proprietary platform of technology designed to enhance drug performance. Its patented mixing process-commercially referred to as PermaFusion-enables stable suspension of polar, water-soluble active pharmaceutical ingredients (APIs) in oil-based carriers without the use of emulsifiers. Its primary development programs focus on dermatological diseases, including moderate to severe eczema and onychomycosis. Its products and programs include GX-03/Hexagen for Wounds (Hexagen (K160872)), GX-03/Hexagen for Derm (AtopX (K171191)), Sterile Gauze Impregnated with GX-03/Hexagen (XEAL (K183681)), Sterile Collagen/Hexagen Powder (FleX Product), GX-03/Hexagen for Moderate-Severe Eczema, and GX-03/Hexagen for Onychomycosis. GX-03/Hexagen for Wounds (Hexagen (K160872)) is a medical device for treating wounds and burns. GX-03/Hexagen for Derm (AtopX (K171191)) is a medical device for managing dermatitis.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
24/07/26	$8.540	-9.92%	99,769
23/07/26	$9.480	-1.46%	67,050
22/07/26	$9.620	-5.50%	50,704
21/07/26	$10.18	+1.29%	171,727
20/07/26	$10.05	+10.20%	196,014

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.540USD

Average target price

26.00USD

Spread / Average Target

+204.45%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 23:00:00 24/07/2026 +03			5-day change	1st Jan Change
8.540 ^USD	-9.92%		-6.36%	+116.75%

07-20	Ladenburg Thalmann Initiates Turn Therapeutics at Buy With $26 Price Target	MT
07-07	Turn Therapeutics Inc. Announces Final Stage 2 Design And Data-Driven Expansion Of GX-03 Phase 2 Program In Atopic Dermatitis	CI

Market Cap	254M 223M 208M 191M 358M 24.5B 364M 2.47B 964M 12.04B 955M 934M 41.64B	P/E 2026 *	-94.9x	P/E 2027 *	-26.7x
Enterprise Value	254M 223M 208M 191M 358M 24.5B 364M 2.47B 964M 12.04B 955M 934M 41.64B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	45.88%	Yield 2026 *	-	Yield 2027 *	-

07-20	Ladenburg Thalmann Initiates Turn Therapeutics at Buy With $26 Price Target	MT
07-07	Turn Therapeutics Inc. Announces Final Stage 2 Design And Data-Driven Expansion Of GX-03 Phase 2 Program In Atopic Dermatitis	CI
07-07	Turn Therapeutics Completes Interim Phase 2 Review; Expands GX-03 Study in Atopic Dermatitis	MT
06-29	Turn Therapeutics Inc.(NasdaqGM:TTRX) added to Russell Microcap Growth Benchmark Index	CI
06-29	Turn Therapeutics Inc.(NasdaqGM:TTRX) added to Russell 3000E Growth Benchmark	CI
06-29	Turn Therapeutics Inc.(NasdaqGM:TTRX) added to Russell Microcap Index	CI
06-29	Turn Therapeutics Inc.(NasdaqGM:TTRX) added to Russell 3000E Index	CI
06-01	Turn Therapeutics reports interim analysis findings and adaptive optimization strategy from phase 2 GX-03 trial in moderate-to-severe atopic dermatitis	RE
06-01	Turn Therapeutics Reports Interim Analysis Findings And Adaptive Optimization Strategy From Phase 2 GX-03 Trial In Moderate-To-Severe Atopic Dermatitis	CI
05-27	Turn Therapeutics Announces Peer-Reviewed Publication Highlighting GX-03 Activity In IL-36 Associated Inflammatory Model	CI
05-18	Turn Therapeutics Inc. Appoints Stephen M. Hahn as Executive Clinical and Regulatory Lead	CI
05-12	Turn Therapeutics reports first quarter 2026 financial results	RE
05-11	Turn Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

07-20	Ladenburg Thalmann Initiates Turn Therapeutics at Buy With $26 Price Target	MT
22/10/25	Turn Therapeutics provides shareholder update highlighting continued execution across clinical and strategic milestones	RE

Turn Therapeutics Inc. Stock

Stocks

TTRX

US90021W1053

Biotechnology & Medical Research

Valuation: Turn Therapeutics Inc.

Chart: Turn Therapeutics Inc.

Latest news : Turn Therapeutics Inc.

Analysts' recommendations: Turn Therapeutics Inc.

Press Releases: Turn Therapeutics Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Turn Therapeutics Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

07-07	Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis	BU
07-06	Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis	BU
06-01	Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis	BU
05-27	Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model	BU
05-19	Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026	BU

1 day	-9.92%
1 week	-6.36%
Current month	+16.99%
1 month	+23.23%
3 months	+140.90%
6 months	+72.18%
Current year	+116.75%

1 week	8.5	10.48
1 month	6.51	11.69
Current year	3.01	11.69
1 year	2.57	26.5
3 years	2.57	26.5
5 years	2.57	26.5
10 years	2.57	26.5

Manager	Title	Age	Since
Bradley Burnam CEO	Chief Executive Officer	48	06/01/2015
Zuraiz Chaudhary DFI	Director of Finance/CFO	31	01/05/2025
Conoon Kim CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Arthur Golden BRD	Director/Board Member	80	01/09/2025
Andrew Gengos BRD	Director/Board Member	61	01/01/2020
Martin Dewhurst BRD	Director/Board Member	62	07/01/2026

Date	Insider	Type	Main position	Quantity	% Market Cap.
6/4/26 A	Andrew Gengos	Free	Director	95,000	0.3189%
6/4/26 A	Martin Dewhurst	Free	Director	71,666	0.2406%
6/4/26 A	Kent Kester	Free	Director	83,334	0.2798%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TURN THERAPEUTICS INC.	-9.92%	-6.36%	-	-	254M
ARGENX SE	+0.93%	+6.97%	+59.60%	+69.78%	57.28B
WUXI APPTEC CO., LTD.	-1.92%	+6.03%	+40.64%	+80.66%	54.99B
INSMED INCORPORATED	-0.46%	-1.29%	+2.86%	+425.15%	23.18B
BIONTECH SE	-2.97%	-2.35%	-22.53%	-15.34%	22.59B
WUXI BIOLOGICS (CAYMAN) INC.	+0.05%	+2.46%	+22.50%	-6.44%	20.46B
GENMAB A/S	-1.34%	+0.51%	+26.03%	-28.68%	17.56B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.29%	+5.67%	+38.77%	+565.80%	15.67B
PHARMAESSENTIA CORPORATION	-1.30%	-5.02%	+170.77%	+310.94%	14.46B
EXELIXIS, INC.	-0.50%	-0.98%	+21.43%	+179.36%	13.92B
Average	-1.87%	+0.51%	+40.01%	+175.69%	24.04B
Weighted average by Cap.	-0.83%	+2.09%	+39.56%	+138.11%

	2026 *	2027 *
Net sales	-	-
Net income	-2.78M -2.44M -2.27M -2.08M -3.92M -268M -3.98M -26.97M -10.54M -132M -10.44M -10.21M -455M	-10.4M -9.13M -8.49M -7.79M -14.64M -1B -14.87M -101M -39.39M -492M -39.03M -38.19M -1.7B
Net Debt	-	-